Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Receives European Marketing Authorization for IMVANEX Smallpox Vaccine
Bavarian Nordic A/S announced that the European Commission has granted marketing authorization for IMVANEX (MVA-BN) for active immunization against smallpox disease for the general adult population, including people with weakened immune systems (people diagnosed with HIV or atopic dermatitis). The authorization covers all 27 European Union member states and European Economic Area countries Iceland, Liechtenstein and Norway. IMVANEX will be made available for governments to purchase and use in accordance with official national recommendations.
Latest Developments forBavarian Nordic A/S
- Share this
- Digg this